ArticleDigital health
Consumer health technology data in the German healthcare system: Stakeholder perspectives, ethical challenges, and governance pathways.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The paper explores how data generated by consumer health technologies can be used responsibly for research in the German healthcare system. It aims to identify perceived benefits, obstacles, and ethical concerns from different stakeholder groups and to interpret these perspectives through the framework of data solidarity. Methods: The study employed an explorative qualitative design: data were collected in cross-sector group discussions, semistructured follow-up interviews, or written responses to the interview guide. Stakeholders included healthcare professionals, statutory health insurance representatives, medical researchers, digital health developers, and experts on data governance and ethics. Results: Stakeholders highlighted several potential benefits of consumer health technology data use, such as patient empowerment, preventive care, advantages for research, and more personalized treatment pathways. At the same time, they pointed to obstacles including lack of interoperability, data quality concerns, and limited trust in commercial actors. Ethical assessments varied depending on the context and purpose of use. Conclusion: The societal value of consumer health technology data depends on the governance conditions under which it is used. Independent infrastructures, reliable standards for data validity, and practices of solidarity are crucial for realizing benefits while addressing risks. Broader stakeholder involvement and more systematic evaluation will be necessary to strengthen future governance approaches. Besides this, we argue that ethical and societal concerns should not be treated as external constraints of innovation, but as constitutive dimensions of equitable and trustworthy digital health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.